Skip to main content
Give
Edit Icon - Click to update your profileUpdate Your Profile

Maka Siamashvili, MD

Academic Title:

Assistant Professor

Primary Appointment:

Medicine

Email:

msiamashvili@som.umaryland.edu

Download CV

Education and Training

  • Master of Business Administration, University of Maryland University College, Baltimore, MD, 2014
  • Medical Doctor, Aieti Medical School, Tbilisi, Georgia
  • Postdoctoral Fellowship. Division of Diabetes, Endocrinology, Metabolism. Vanderbilt University, Nashville, TN. Mentor: Stephen N Davis, MBBS
  • Internship/Specialty Training. Pediatric Cardiology. Jo Ann Medical Center. Tbilisi, Georgia. Mentor: Vakhtang Khelashvili, MD

Biosketch

Maka Siamashvili, MD, MBA, is a graduate of Aieti Medical School. She trained in cardiology at Jo Ann Medical Center in Tbilisi, Georgia and completed a postdoctoral research fellowship at Vanderbilt University in Nashville, TN. She is also a 2014 Phi Kappa Phi graduate of the University of Maryland University College Master in Business Administration program.

In December 2009, Dr. Siamashvili joined the faculty of the University of Maryland. She investigates mechanisms that defend against hypoglycemia (low blood sugar). Some of the projects she has been working on are: (1) How different levels of hypoglycemia affect the blood vessels; (2) How the selective serotonin re-uptake inhibitor, fluoxetine (Prozac), an antidepressant often used to treat depression, affects body’s ability to defend itself from hypoglycemia that can occur during or after exercise; (3) How alprazolam (Xanax), an anti-anxiety drug, affects specialized molecules in the brain called GABA (A) receptors that alter the body’s ability to defend itself from hypoglycemia.

Dr. Siamashvili has published over 35 original and review articles and has also served as a peer reviewer.

Research/Clinical Keywords

Type 1 diabetes, GABA, exercise, hypoglycemia, xanax, fluoxetine

Highlighted Publications

  • Hedrington MS, Mikeladze M, Tate DB, Younk LM, Davis I, Davis SN. Effect of GABA A receptor activation on counterregulatory responses to subsequent exercise in individuals with type 1 diabetes. Diabetes. 2016.
  • Hedrington MS, Tate DB, Younk LM, Davis SN. Effect of antecedent GABA A receptor activation on counterregulatory responses to exercise in healthy man. Diabetes. 2015 Apr 21. doi:pii: db150212. PMID: 25901095
  • Hedrington MS, Farmerie S, Tate DB, Ertl AC and Davis SN. The Effects of GABAA Activation on Subsequent Counterregulatory Responses to Hypoglycemia in Healthy Man. Diabetes. 2010 Apr;59(4):1074-81

Additional Publication Citations

Peer Reviewed Articles

  1. Gogitidze N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC and Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33(7):1529-35.
  2. Wang Z, Hedrington MS, Gogitidze Joy N, Briscoe VJ, Richardson MA, Younk L, Nicholson W, Tate DB and Davis SN.  Dose response effects of insulin glargine in type 2   Diabetes Care 2010;33(7):1555-60.
  3. Hedrington MS, Puliam L and Davis SN. Basal Insulin Treatment in Type 2 Diabetes. Diabetes Technology and Therapeutics. 2011 Jun;13 Suppl 1:S33-42. Review.
  4. Younk LM, Hedrington MS, Davis SN. Hypoglycemia associated with exercise in diabetes. Diabetic Hypoglycemia 2011;4:3-10.
  5. Hedrington MS, Davis SN. Discontinued drug therapies to treat diabetes in 2015. Expert Opin Investig Drugs. 2016 Dec 26;PubMed PMID: 27997806.
  6. Mikeladze M, Hedrington MS, Joy N, Tate DB, Younk LM, Davis I, et al. Acute Effects of Oral Dehydroepiandrosterone on Counterregulatory Responses During Repeated Hypoglycemia in Healthy Humans. Diabetes. 2016;65(10):3161-70
  7. Hedrington MS, Davis SN. The care of pregestational and gestational diabetes and drug metabolism considerations. Expert Opin Drug Metab Toxicol. 2017 Sep 5;:1-10. PubMed PMID: 28847172.
  8. Hedrington MS, Davis SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):671-677
  9. Lamos E, Hedrington MS, Davis SN. Use of anti-diabetes therapies in individuals with type 2 diabetes and NAFLD. In Manuscript
  10. Stein SA, Lamos EM, Hedrington MS, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. In Manuscript
  11. Hedrington MS, Mikeladze M, Tate DB, Joy GJ, Davis SN. Differential Effects of Antecedent GABA (A) activation on Counterregulatory Responses to Exercise in Type 1 Diabetic and Non Diabetic man. In Manuscript

Textbook Chapters and Review Articles

  1. Hedrington MS, Davis, SN. Discontinued drugs in 2013:    Expert Opinion on Investigational Drugs.  2014, Dec; 23(12); 1703-11. 
  2. Davis SN, Tate DB, Hedrington MS. Mechanisms of hypoglycemia and exercise associated autonomic dysfunction. Transactions of the American clinical and climatological association, vol. 125, 2014
  3. Hedrington MS and Davis SN. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):613-23.
  4. Hedrington MS, Davis SN. Sexual dimorphism in glucose and lipid metabolism during fasting, hypoglycemia and exercise.  Front Endocrinol (Lausanne). 2015 Apr 27;6:61.
  5. Hedrington MS, Davis SN. The role of empagliflozin in the management of type 2 diabetes by patient profile.  Ther Clin Risk Manag. 2015 May 5;11:739-49.
  6. Sandoval DA, Lamos EM, Younk LM, Hedrington MS, Davis SN. Reference Module in Biomedical Sciences. Elsevier. 2018
  7. Hedrington MS, Davis SN. Peroxisome proliferator-activated receptor alpha-mediated drug toxicity in the liver. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):671-677. doi: 10.1080/17425255.2018.1483337. Epub 2018 Jun 7. Review. PubMed PMID: 29847748.
  8. Hedrington MS, Tsiskarishvili A, Davis SN. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Expert Opin Biol Ther. 2018 Mar;18(3):343-351. doi: 10.1080/14712598.2018.1439014. PubMed PMID: 29431519.
  9. Hedrington MS, Davis. Oral semaglutide for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019 Feb;20(2):133-141. doi: 10.1080/14656566.2018.1552258. Epub 2018 Nov 30. Review. PubMed PMID: 30499733.
  10. Lamos EM, Hedrington M, Davis SN. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf. 2019 Aug;18(8):691-701. doi: 10.1080/14740338.2019.1626823. Epub 2019 Jun 7. Review. PubMed PMID: 31150300.
  11. Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2019 Dec;20(18):2229-2235. doi: 10.1080/14656566.2019.1672660. Epub 2019 Oct 8. Review. PubMed PMID: 31593486.
  12. Siamashvili M, Davis SN. Late phase completed clinical trials investigating bromocroptine mesylate quick release as treatment of type 2 diabetes mellitus. 2020 Oct 8;1-7. doi: 10.1080/14656566.2020.1825683

Abstracts

  1. Briscoe VJ, Bao S, Ertl AC, Hedrington MS, Gilliam J, Tate DB and Davis SN. Effects of antecedent physiologic plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes.  58: A284-A285, 2009.
  2. Wang Z, Briscoe VJ, Hedrington MS, Gogitidze N, Richardson A, Ertl AC and Davis SN. Physiologic dose response effects of insulin glargine in type 2 diabetes. Diabetes. 58, 2009.
  3. Hedrington M, Briscoe, VJ, Tate DB, Younk LM, Davis SN. The effects of antecedent GABA A receptor activation on counterregulatory responses to exercise in healthy man.  Diabetes 59:A319, 2010.
  4. Gogitidze Joy N, Perkins JM, Richardson A, Hedrington, M, Younk L, Davis, I, Tate DB and Davis SN. Acute effects of Hypoglycemia and Hyperglycemia on Pro-Atherothrombotic Risk in non Diabetic Humans.   Diabetes 60:A480, 2011.
  5. Gogitidze Joy N, Mikeladze M, Hedrington M, Younk L, Pulliam L, Davis, I, Tate DB and Davis SN. Effects of Hypoglycemia on Endothelial Function and Atherothrombotic Balance in Type 2 Diabetes (T2DM).  Diabetes 60:A481, 2011.
  6. Hedrington M, Mikeladze M, Joy NG, Young C, Tate, DB, Pulliam L, Younk L, Davis I, Younk C, Davis SN. Effects of antecedent GABA A receptor activation on counterregulatory responses to subsequent exercise in type 1 diabetes. Diabetes 61:A382, 2012. and 2012 Mid-Atlantic Diabetes Research Symposium. Oral presentation
  7. Joy NG, Young C, Tate, DB, Hedrington M, Mikeladze M, Davis I, Pulliam L, Younk L, Younk C, Davis SN. Effects of Insulin and Combined Hyperglycemia and elevated FFA on Endothelial Function, adhesion molecules and Platelet Aggregation in Healthy Man. Diabetes 61: A399, 2012.
  8. Hedrington M, Tate DB, Mikeladze M, Joy GJ, Davis SN. Differential Effects of Antecedent GABA (A) activation on Counterregulatory Responses to Exercise in Type 1 Diabetic and Non Diabetic man. Diabetes 62: A172, 2013.
  9. Mikeladze M, Joy NG, Hedrington M, Young C, Tate DB, Davis, I, Pulliam L, Younk L, and Davis SN. The Effects of Dehydroepiandrosterone on Counterregulatory Responses during Repeated Hypoglycemia in Healthy Volunteers.  Diabetes 62: A258, 2013. Oral presentation
  10. Mikeladze M, Joy NG, Hedrington M, Tate DB, Young C, Pulliam L, Younk L, and Davis SN. The Effects of 6 weeks Dehydroepiandrosterone (DHEA) on Counterregulatory Responses during Repeated Hypoglycemia in Healthy Humans.  Diabetes 63: Suppl.1, A65, 2014. Oral presentation
  11. Mikeladze M, Joy NG, Hedrington M, Tate D, Young C, Younk L, Pulliam L, Davis SN. Effects of 6 weeks atomoxetine on counterregulatory responses during repeated hypoglycemia in healthy individuals.  Diabetes. 64: A395, 2015. Guided audio tour
  12. Joy NG, Mikeladze M, Tate D, Hedrington M, Younk L, Davis SN. Effects of atomoxetine on symptom awareness and cognitive function during repeated hypoglycemia in healthy individuals.  Diabetes. 64: A396, 2015. Guided audio tour
  13. Hedrington M, Mikeladze M, Tate DB, Joy GJ, Younk LM, Thayer E and Davis SN. Effects of differing levels of hypoglycemia on vascular biologic mechanisms in healthy individuals. Diabetes 65: 2017. Oral presentation
  14. Mikeladze M, Hedrington MS, Joy N, Dumbadze S, Briscoe V, Tate D,  Thayer E, and Davis SN. Hypoglycemia associated autonomic dysfunction, dose response of epinephrine. Diabetes 66: 2018. Oral presentation
Edit Icon - Click to update your profileUpdate Your Profile